obinutuzumab (Gazyva)
Jump to navigation
Jump to search
Indications
- treatment-naive patients with chronic lymphocytic leukemia
- for use with chlorambucil
- 1st line treatment of follicular lymphoma[2]
- lupus nephritis: for use with mycophenolate & glucocorticoid[4]
Adverse effects
- infusion-related reactions
- associated with severe COVID-19 infection[3]
- boxed warning
- potential risks for hepatitis B virus reactivation & progressive multifocal leukoencephalopathy
Mechanism of action
- humanized type II anti-CD20 monoclonal antibody
More general terms
References
- ↑ FDA News Release: Nov. 1, 2013 FDA approves Gazyva for chronic lymphocytic leukemia http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373209.htm
- ↑ Jump up to: 2.0 2.1 2.2 Marcus R, Davies A, Ando K et al Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 2017; 377:1331-1344. October 5, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28976863 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1614598
- ↑ Jump up to: 3.0 3.1 Ingram I Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients - Plus: Active chemo treatment may not be a COVID risk factor. MedPage Today February 5, 2021 https://www.medpagetoday.com/hematologyoncology/lymphoma/91092
- ↑ Jump up to: 4.0 4.1 Monaco K Obinutuzumab for Lupus Nephritis Boosts Complete Remissions. Positive phase III data being shared with FDA. MedPage Today. February 7, 2025 https://www.medpagetoday.com/rheumatology/lupus/114139
Furie RA et al Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N Engl J Med. 2025. Feb 7. Not yet indexed in PubMed https://www.nejm.org/doi/full/10.1056/NEJMoa2410965